Manuscript Topics

It has been just over ten years since the Nobel Prize winning discovery in Physiology and Medicine by Dr. Shinya Yamanaka (2012) that mature cells can be ‘reprogrammed’ to become pluripotent stem cells with the ability to give rise to any other cell type in the body. This discovery dramatically changed our view of cell fate and plasticity and has heralded a renaissance in the field of regenerative medicine approaches. Since this discovery many researchers worldwide have used these iPS cell technologies in order to create patient-specific stem cells that can model aspects of cellular dysfunction and disease in vitro when differentiated to a specific cell type of interest such as cardiomyocytes or neurons. The use of these patient-derived stem cells to better understand disease holds great promise as a drug-screening tool that can be used to develop novel therapeutics. The real promise of this technology rests in the ability to develop iPS cells that can eventually be used in vivo to repair damaged and diseased tissue in a safe and efficacious manner. Clearly, a decade after its initial discovery many barriers still exist before iPS cells can be used in clinical settings and trials. In this special issue we are seeking both review and primary research articles that are state of the art with regards to iPS cell use in vitro, as well as in pre-clinical in vivo animal trials that have relevance to human disease. Authors are encouraged to submit an abstract for initial review. The guest editor will then encourage a full submission, if appropriate.

Instructions for authors
http://awstest-alb.aimspress.com/cte/news/solo-detail/instructionsforauthors
Please submit your manuscript to online submission system
http://oeps.aimspress.com/ate/ch/author/login.aspx